Company news
Nuformix Plc (LSE:NFX) news
Nuformix Plc news releases on 6ix. Latest, Jul 5, 2022: NXP002 data to be presented at 2022 ERS Congress
Press releases — page 2
NXP002 data to be presented at 2022 ERS Congress
July 5, 2022
NXP004 Update
June 29, 2022
Directorate Change
May 31, 2022
Corporate Update
May 30, 2022
Second tranche of Lanstead subscription shares
April 12, 2022
NXP004 Patent
March 28, 2022
Appointment of Dr Dan Gooding as Consultant
March 2, 2022
Oxilio NXP-001 formulation development contract
February 8, 2022
Adviser Appointments
February 1, 2022
Director/PDMR Shareholding
January 31, 2022
Posting of Circular and Notice of General Meeting
January 17, 2022
Second Price Monitoring Extn
December 14, 2021
Positive pre-clinical data on NXP002
November 25, 2021
NXP004 patent application filing
November 12, 2021
Price Monitoring Extension
October 4, 2021
Director/PDMR Shareholding - Replacement
September 16, 2021
Licensing agreement with Oxilio for NXP001
September 13, 2021
Letter to shareholders re: Dr Anne Brindley
July 22, 2021
Final results for the year ended 31 March 2021
July 15, 2021
Notice of Allowance of Patent in US
June 7, 2021
Project update - Progress on NXP002 and NXP004
June 1, 2021
Directorate Changes
May 24, 2021
Correction: Holding(s) in Company
April 8, 2021
Result of General Meeting and Total Voting Rights
March 29, 2021
NXP001 (Oncology) - Exercise of Option by Oxilio
March 22, 2021
Initiation of research by Allenby Capital
March 11, 2021
Proposed Placing to raise £1.565 million
March 10, 2021
Research Results
March 2, 2021
Appointment of Broker
December 22, 2020
Appointment of Chief Executive Officer
December 7, 2020
Appointment of Non-Executive Director
December 2, 2020
Placing and Strategic Update
October 7, 2020
Exclusive Option Agreement for NXP001
September 24, 2020
Results Pre-clinical Pilot Study in IPF for NXP004
August 19, 2020
Annual Report and Notice of AGM 2020
July 28, 2020
Preliminary Results for year ended 31 March 2020
July 22, 2020
Notification of Major Holdings
July 1, 2020
Board Change
June 22, 2020
Business Update
May 27, 2020
Notiication of Major Share Holding
March 30, 2020
Appointment of Dr Karl Keegan
February 18, 2020
Operational Update
February 5, 2020
Resignation of John Lidgey
January 27, 2020
Amendment to Notice
January 15, 2020
Issue of Equity
January 10, 2020
Update and Placing Announcement
November 25, 2019
Statement re. Share Price Movement
October 25, 2019
AGM Results
September 10, 2019
Ebers Cannabinoid Collaboration Update
September 9, 2019
Appointment of Dr Muhunthan Thillai
September 6, 2019